Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?

Introduction: The term theragnostic refers to the combination of a predictive imaging biomarker with a therapeutic agent. The promising application of prostate-specific membrane antigen (PSMA)-based radiopharmaceuticals in the imaging and treatment of prostate cancer (PCa) patients opens the way to...

Cijeli opis

Bibliografski detalji

Glavni autori:	Francesco Dondi, Alberto Miceli, Guido Rovera, Vanessa Feudo, Claudia Battisti, Maria Rondini, Andrea Marongiu, Antonio Mura, Riccardo Camedda, Maria Silvia De Feo, Miriam Conte, Joana Gorica, Cristina Ferrari, Anna Giulia Nappi, Giulia Santo
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2024-07-01
Serija:	Bioengineering
Teme:	PSMA radioligand therapy solid tumours non-prostate luthetium-177
Online pristup:	https://www.mdpi.com/2306-5354/11/7/714
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!